FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/07/2023
Back to search
Official data from USPTO
TELUM THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
25
Latest update
08/07/2023
Trademark type
Combined
Nice classes
1, 5, 42
Filing date
09/27/2021
Registration date
03/28/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/28/2023
Last transaction
03/28/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
16
Owner location
ES
Examiner
MESSICK, TABITHA
Law office
L40
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stacked wording "TELUM THERAPEUTICS" in purple. Beside the wording are two single line triangles with an open bottom and a single line polygon in the middle. The color of this design is a gradient from yellow to orange to purple. The white in the mark is for transparent purposes and is not claimed as a feature of the mark.
Holders and representatives
Holders
T. S. (pessoa física)
Representatives
John G. Tutunjian Tutunjian & Bitetto, P.C.
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Diagnostic preparations for scientific purposes; reagents for medical research use; reagents for medical research in the field of infectious diseases and diseases caused by bacteria; diagnostic reagents for scientific or research use; enzymes for scientific purposes; diagnostic kits comprising specimen receptors being biological tissues cultures and reagents for testing for selected bacteriaother than for medical or veterinary use
Class 5
Pharmaceutical products for the treatment of infectious diseases; pharmaceutical products for the treatment of diseases caused by bacteria; antibacterial pharmaceuticals; antibiotics; pharmaceutical preparationsbiopharmaceuticals for the treatment of infectious diseases; pharmaceutical preparationsimmunotherapeutic agents for bacterial infections; enzyme preparations for medical purposes; enzymes for medical purposes; enzymes and enzyme preparations for medical purposes for the diagnosisprognosis and treatment of infectious diseases and diseases caused by bacteria; assaysbiomarkers and reagents for medical purposes for the diagnosisprognosis and treatment of infectious diseases and diseases caused by bacteria
Class 42
Biomedical research services; scientific research for medical purposes in the field of infectious diseases and diseases caused by bacteria; research and development of pharmaceutical productsantibioticsassaysbiomarkers and reagents for the diagnosisprognosis and treatment of infectious diseases and diseases caused by bacteria; research and development of immunotherapeutic agents for bacterial infections; research and development of enzymesenzyme preparations and synthetic proteins for the diagnosisprognosis and treatment of infectious diseases and diseases caused by bacteria; conducting clinical trials for others of pharmaceutical productsantibioticsassaysbiomarkers and reagents for the diagnosisprognosis and treatment of infectious diseases and diseases caused by bacteria
Publications
History of USPTO decisions and trademark events.
25 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/18/2023
FIMP
FINAL DISPOSITION PROCESSED
07/18/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/28/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/28/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
03/28/2023
GPNX
NOTIFICATION PROCESSED BY IB
01/24/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/10/2023
PUBO
PUBLISHED FOR OPPOSITION
01/10/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/04/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/04/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/21/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/02/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/17/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/16/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/16/2022
RFNT
REFUSAL PROCESSED BY IB
08/23/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/29/2022
RFRR
REFUSAL PROCESSED BY MPU
07/29/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/03/2022
CNRT
NON-FINAL ACTION WRITTEN
07/02/2022
DOCK
ASSIGNED TO EXAMINER
06/28/2022
MAFR
APPLICATION FILING RECEIPT MAILED
11/23/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/19/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/18/2021
Continuous trademark protection
Get notified about every new filing that threatens TELUM THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.